Forbes features CLCC
Press releases
Calla Lily Clinical Care doses first patients in clinical trial for intravaginal drug delivery platform for threatened miscarriage
FREEDOM study to evaluate progesterone delivery using Callavid intravaginal platform NIHR-funded trial in collaboration with University Hospitals Coventry and Warwickshire NHS Trust London, UK – Calla Lily Clinical Care, a women’s health-focused medical technology company, today announced dosing of the first patients in the FREEDOM clinical trial. The study, funded by the National Institute for …
Calla Lily Clinical Care and Merck announce Strategic Collaboration to advance Intravaginal Drug Delivery Platform
London, UK – Calla Lily Clinical Care, a women’s health-focused medical technology company, and Merck, a leading science and technology company, have entered a strategic collaboration to support the continued development of Callavid®, a novel platform for intravaginal drug delivery. The collaboration represents the first industry partnership for the Callavid® technology. Callavid is a transformational leak-resistant …
Pioneering technology to address threatened miscarriage secures £1 million funding and moves towards clinical trials
London, UK – A team of scientists and biomedical engineers developing pioneering technology designed to treat threatened miscarriage has secured £1 million in Invention for Innovation (i4i) funding from the National Institute for Health and Care Research (NIHR) for its first clinical trial. The new technology is a novel device designed to improve the delivery …
